Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Conditions: Hepatocellular Carcinoma; Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancers; Esophageal Squamous Cell Carcinoma; Triple Negative Breast Cancer; Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer; Head and Neck Squamous-Cell Carcinoma Interventions: Drug: ABBV-400 Sponsors: AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Esophagus Cancer | Head and Neck Cancer | Hepatocellular Carcinoma | HNSCC | Hormones | Liver Cancer | Pancreas | Pancreatic Cancer | Research | Skin Cancer | Squamous Cell Carcinoma | Study